
Viaskin Peanut Patch Shifts Peanut Allergy Biomarkers in VITESSE
In VITESSE, peanut-specific IgG4 rose about 5-fold in children aged 4 to 7 years, David Fleischer, MD, told HCPLive at ACAAI 2026.
Epicutaneous immunotherapy (EPIT) with the investigational Viaskin Peanut Patch raised peanut-specific immunoglobulin G4 (psIgG4) and lowered
VITESSE previously met its primary endpoint, with 46.6% of children receiving the patch meeting responder criteria at 12 months compared with 14.8% of children receiving placebo (difference, 31.8%; 95% CI, 24.5–39.0; P <.001).² DBV Technologies has since submitted a Biologics License Application (BLA) to the FDA for the patch in children aged 4 to 7 years.³ The new analysis assessed biomarkers longitudinally to determine whether they could help clinicians monitor patients receiving EPIT.¹
“I think the biggest thing is epicutaneous immunotherapy is immunomodulatory,” said David Fleischer, MD, director of the Allergy and Immunology Center at Children’s Hospital Colorado, in an interview with HCPLive at ACAAI 2026. “It does affect the immune system to induce some protection and increase tolerance to peanuts.”
Peanut Allergy Biomarker Changes With EPIT in VITESSE
VITESSE randomized 654 children with peanut allergy 2:1 to the Viaskin Peanut Patch containing 250 µg of peanut protein (VP250) or placebo.¹ Investigators evaluated changes from baseline in psIgG4, psIgE, Ara h 2 IgE, and SPT wheal diameter using repeated-measures analysis of covariance models.¹
Median psIgG4 increased in the VP250 group relative to placebo by month 3 and remained elevated through month 12 (least-squares mean [LSM] ratio, 4.93; 95% CI, 4.42–5.50; P <.001).¹ At month 12, median psIgE was 14% lower with VP250 versus placebo (LSM ratio, 0.86; 95% CI, 0.78–0.94; P =.001).¹ Median Ara h 2 IgE was 30% lower (LSM ratio, 0.70; 95% CI, 0.64–0.77; P <.001), and mean SPT wheal diameter was 26% smaller (LSM ratio, 0.74; 95% CI, 0.69–0.79; P <.0001).¹
Fleischer, senior author of the analysis, said the early psIgG4 rise is a reassuring sign the therapy is working and could become a marker to predict which patients will respond well. He added responders in the trial had elevated IgG4 and reduced IgE levels, though the abstract did not report a formal correlation analysis. Investigators concluded the changes are consistent with other forms of allergen immunotherapy.¹
Monitoring EPIT With Skin Prick Testing and IgE in Practice
Fleischer said it remains unclear why Ara h 2 IgE declined more than whole-peanut IgE. Across immunotherapy modalities, IgE levels tend to rise during the first 3 to 6 months, peak near month 6, and return toward baseline by month 12, he explained.
Of the available markers, Fleischer favors SPT as a quick, low-burden surrogate. Families can see a smaller wheal within 15 minutes without a blood draw, and his center performs SPT about 18 months into oral and sublingual immunotherapy to show parents evidence of immunomodulation. He said it is not yet clear whether a shrinking wheal predicts reaction risk, and because EPIT delivers a low dose, a food challenge will eventually be needed to confirm response.
Fleischer described psIgG4 testing as largely a research tool, since it is harder to obtain and may not be covered by insurance. SPT may show change as early as 6 months into therapy and could support a decision to continue treatment when a challenge is not planned, he said.
“I generally don’t test for IgE until 18 to 24 months into therapy,” Fleischer said. “There’s no rush to do these things.”
References
Anvari S, Gagnon R, Begin P, et al. Immunologic changes in VITESSE: a 12-month study of epicutaneous immunotherapy in children with peanut allergy. Presented at: American College of Allergy, Asthma & Immunology Annual Scientific Meeting; November 12-16, 2026; Phoenix, AZ.
Derman C. VIASKIN Peanut Patch Effective in Peanut-Allergic Children Aged 4–7 Years. HCPLive. Published December 17, 2025. Accessed November 20, 2026.
https://www.hcplive.com/view/viaskin-peanut-patch-effective-peanut-allergic-children-aged-4-7 Derman C. Viaskin Peanut Patch BLA Submitted for Peanut Allergy in Children Aged 4-7 Years. HCPLive. Published October 1, 2026. Accessed November 20, 2026.
https://www.hcplive.com/view/viaskin-peanut-patch-bla-submitted-peanut-allergy-children-4-7-years
Related to this article








